Session 2J

Diabetes, Endocrine and Cancer

3:30 PM to 5:00 PM | Moderated by Ian Sweet


Tyrosine Degradation, Insulin Signaling and Aging in Caenorhabditis elegans
Presenter
  • Arianne Aslamy, Senior, Biochemistry Amgen Scholar
Mentors
  • Weiqing Li,
  • Victor Pineda,
Session
  • 3:30 PM to 5:00 PM

Tyrosine Degradation, Insulin Signaling and Aging in Caenorhabditis elegansclose

The degradation of tyrosine to produce energy is an essential and highly conserved biochemical pathway among eukaryotes. In humans, mutations in any one of the enzymes involved in this five-step pathway can lead to serious medical consequences. The most severe of which, called Tyrosinemia Type I, is caused by a mutation in the last enzyme of the pathway and can lead to liver failure, neurologic crises, and even death. A recent study on Type I Tyrosinemia by Fisher et. al, 2008 established Caenohabditis elegans as a model for the investigation of Tyrosinemia and suggested a link between the tyrosine degradation pathway and the aging mechanisms. While the connection between the tyrosine degradation aging pathways remains largely unexplored, our research aims to determine whether the tyrosine pathway shares downstream components with insulin signaling, and whether these two pathways work synergistically to regulate aging mechanisms in c.elegans. By employing RNA interference (RNAi) technology, our preliminary results have identified the gene encoding tyrosine aminotransferase (the first enzyme of the degradation pathway) as an enhancer of the long-living dauer (diapausal) phenotype using a mutant of DAF-2 (insulin receptor). Our series of experiments also suggest that dauer formation is likely due to the lack of intermediate tyrosine degradation products, which may constitute a signal that synergizes with insulin signaling. Furthermore, our preliminary quantitative real-time PCR results indicate that in daf-2 mutants, RNAi knock-down of the tyrosine aminotransferase alters the expression level of downstream insulin signaling targets. Ultimately, this investigation of synergisms between the tyrosine degradation pathway and insulin signaling in c. elegans could potentialy give us new insight into how tyrosine metabolism works within the context of mammalian systems, and be of great medical importance with respect to treating diseases such as Tyrosinemia.


Effect of the Anti-Diabetic Drug Metformin on Invasive Cancer Cell Proliferation
Presenter
  • Rebecca Ann (Rebecca) Coil, Senior, Biology (Molecular, Cellular & Developmental) Mary Gates Scholar
Mentors
  • Warren Ladiges,
  • Christina Pettan-Brewer,
Session
  • 3:30 PM to 5:00 PM

Effect of the Anti-Diabetic Drug Metformin on Invasive Cancer Cell Proliferationclose

Metastasis to distant organs is the unfortunate consequence of late-stage human cancer. Treatment has an alarmingly high rate of failure because effective targets have not been identified. For example, melanoma cancer’s incidence rate has been increasing, especially within the youth population. Second to non-metastatic skin cancer, breast cancer is the most common form of cancer and has the highest incidence in American women. Inherent or acquired tumor drug resistance and dose-limiting toxicity limit many agents used to treat these types of cancer. Tumor invasiveness is associated with moderately increased levels of reactive oxygen species (ROS), which can be counteracted with antioxidants. Metformin, a nontoxic drug globally used to effectively treat type 2 diabetes, has been shown to have anti-tumor activity, but the mechanism is not known. Metformin decreases gluconeogenesis and increases glucose uptake, resulting in decreased blood sugar, decreased ROS levels, and decreased tumor incidence. Therefore, the hypothesis of this project is that metformin acts as an antioxidant by preventing the generation of ROS that drives tumor proliferation. This hypothesis will be addressed by treating two tumor cell lines, representing invasive breast cancer and melanoma, with metformin singly, or in combination with a known ROS inhibitor N-acetylcysteine (NAC). NAC is an antioxidant approved for human consumption that acts in the mitochondria to neutralize ROS. If tumor proliferation and ROS levels are decreased in the presence of metformin and NAC, then metformin likely has antioxidant activity with the possibility that the combination may enhance anti-tumor effects. Contrastly, if NAC neutralizes the anti-tumor effect of metformin, then metformin may increase ROS leading to tumor cell death through apoptosis. Data generated from this project will be helpful in determining whether metformin and NAC might be able to be used in combination to treat and prevent metastatic disease such as melanoma and breast cancer.


Characterization of a High-Energy Process that Couples Calcium Influx to Insulin Secretion in the INS-1 Cell Line
Presenter
  • Mark James (Mark) Lisowski, Senior, Biology (Molecular, Cellular & Developmental), Biochemistry Mary Gates Scholar, NASA Space Grant Scholar, Washington Research Foundation Fellow
Mentor
  • Ian Sweet,
Session
  • 3:30 PM to 5:00 PM

Characterization of a High-Energy Process that Couples Calcium Influx to Insulin Secretion in the INS-1 Cell Lineclose

Dysfunction of pancreatic β-cells leading to inadequate insulin secretion is a major determinant in the development of diabetes. Therefore, a detailed understanding of the intracellular processes that mediate insulin secretion rate (ISR) is critical to advancing diabetes research. In rat islets, glucose stimulates an increase in calcium influx and the reduction of cytochrome c. Both of these factors appear to be essential for insulin secretion. Calcium blockade in islets reduces glucose-stimulated ISR to basal levels, and concurrently decreases glucose-stimulated oxygen consumption rate (OCR, a measure of ATP turnover) by 30%. This suggests that a highly energetic, calcium-sensitive process regulates insulin secretion in islets. Our current research characterizes this process in the INS-1 rat insulinoma cell line in order gain more insight into the regulatory process itself, and to evaluate the usefulness of INS-1 cells as a model for diabetes research. Although glucose-stimulated INS-1 cells exhibited cytochrome c reduction similar to normal islets, their ISR was only about 10% of what islets normally secrete. Calcium blockade in INS-1 cells reduced glucose-stimulated insulin secretion to basal levels, and caused a concurrent 15% decrease OCR (versus 30% in rat islets). This suggests that the calcium-sensitive process mediating insulin secretion is less active in INS-1 cells compared to islets. Inhibition of this process via KN-62, a calmodulin-dependent kinase inhibitor, had the same effect on OCR and ISR as calcium blockade. Epinephrine, an inhibitor of exocytotic machinery, was found to inhibit glucose-stimulated ISR without affecting OCR. This suggests that exocytosis of insulin requires relatively little ATP, and is distinct from the highly energetic, calcium-sensitive process we are interested in. In summary, this data supports that a calcium-sensitive, highly energetic process regulates ISR in both rat islets and INS-1 cells. Dysfunction of this regulatory mechanism represents a possible cause for diabetes.


Erythropoietin Receptor Expression and Function in Multiple Myeloma
Presenter
  • Yan Zhang, Junior, Exchange - Arts & Sciences
Mentors
  • C. Anthony Blau,
  • Chris Miller,
  • Kyle Rattray,
Session
  • 3:30 PM to 5:00 PM

Erythropoietin Receptor Expression and Function in Multiple Myelomaclose

 Erythropoietin (Epo) controls red blood cell production by binding to its receptor (EpoR) on the surface of erythroid progenitor cells and is used to treat the anemia of renal failure and cancer. However, adverse effects of Epo treatment on cancer survival were observed in recent clinical trials. Whether EpoR is present and functional on cancer cells remains controversial. In this study we tested whether the EpoR is present and functional on the surface of multiple myeloma cells. The first step was to choose credible anti-EpoR antibodies. We tested the specificity of Amgen A82 and R+D FAB307P antibodies in EpoR+ OCIM1 cell clones expressing a wide range of EpoR created by lentiviral shRNA knockdown. Results showed that both antibodies were specific and produced similar results in the OCIM1 shRNA panel (correlation coefficient, r=0.90, p=0.02, n=5) and in a panel of hematopoietic cell lines (r=0.71, p=0.007, n=11). We then measured EpoR in 5 primary patient myeloma samples using FAB307P and A82 antibodies. We detected a 10 fold range of staining intensity with FAB307P but no signal with A82. Because these findings in primary cells differ from the previous results in cell lines, we next tested the effect of Epo on EpoR internalization. This idea was based on the well-known principle that Epo causes endocytosis of the EpoR, resulting in a decreased level of EpoR on the cell surface. We found that EpoR internalization occurs in OCIM1, UT7Epo and U266 cell lines after Epo treatment, with a reduced EpoR signal for both FAB307P and A82 antibodies. We further applied this idea in primary myeloma samples, but did not detect significant differences in the EpoR signal between Epo treated and control cells in 2 samples tested to date. Future studies will examine Epo internalization in additional primary myeloma samples and assess Epo-induced signal transduction.


The University of Washington is committed to providing access and accommodation in its services, programs, and activities. To make a request connected to a disability or health condition contact the Office of Undergraduate Research at undergradresearch@uw.edu or the Disability Services Office at least ten days in advance.